drugset / Trial / NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Timeline
- Start
- 2024-04-26
- Primary completion
- 2026-03-15
- Completion
- 2027-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REM-422 | Small molecule | — | Oral |